Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Based on the pre-clinical data the investigators hypothesize that G-CSF treatment in patients
with multiple myeloma will generate a 'hostile' bone marrow microenvironment for myeloma
cells, depriving them of key support signals and rendering them more sensitive to
chemotherapy. The investigators therefore propose to do an initial pilot study 1) to explore
the safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment
regimens in patients with bortezomib-, carfilzomib-, or IMID-refractory myeloma and 2) to
generate correlative data for a subsequent larger study looking at the combination.